– Blackstone announced the final close of Blackstone Life Sciences VI (“BXLS VI”).
– BXLS VI was oversubscribed and closed at its hard cap of $6.3 billion in total capital commitments.
– BXLS VI is the largest life sciences private fund ever raised, nearly 40% larger than its predecessor.
– Nicholas Galakatos, Ph.D., Global Head of Blackstone Life Sciences, expressed gratitude to investors for their support and highlighted the firm’s strong track record.
– BXLS partnerships have produced 34 regulatory approvals of innovative medicines and devices.
– The BXLS platform, launched in 2018, invests across the life cycle of companies and products in key life science sectors.
– BXLS had $15 billion in assets under management as of Q4 2025.
– The platform leverages deep domain expertise, global industry relationships, and scale capital to finance the development and commercialization of new medicines and technologies.
– Notable products supported include blockbuster medicines LEQVIO®, AMVUTTRA®, IMBRUVICA®, and devices like MiniMed Flex™.
– BXLS has an 86% approval success rate for Phase III assets, outperforming the industry average and delivering strong performance for investors.
